May 22, 2013

European Commission grants Marketing Authorisation for HyQvia

Baxter and Halozyme Therapeutics announced yesterday that they have received a marketing authorization from the European Commission for HyQvia as a treatment for adults with primary and secondary immunodeficiencies.  This follows a positive opinion for the product from the European Medicines Agency’s Committee for Medicinal Products for Human Use earlier this year. For more information, please see the attached press release.

World PI Week
IPOPI would be grateful for any support to the important work for primary immunodeficiencies.

Read all

Executive Director: Johan Prevot
Tel/Fax: +351 21 407 5720
UK office
Firside Main Road Downderry
Cornwall PL11 3LE
United Kingdom

Tel: +44 1503 250 668
Fax: +44 1503 250 961
IPOPI is a charity registered in the UK.
Registration No. 1058005